{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:18:10Z","timestamp":1790882290129,"version":"4.1.0"},"reference-count":27,"publisher":"Ordem dos Medicos","issue":"5","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Med Port"],"abstract":"<jats:p>A terap\u00eautica substitutiva com imunoglobulina \u00e9 parte essencial do tratamento dos erros inatos da imunidade que comprometem a resposta humoral. O seu principal objetivo \u00e9 fornecer anticorpos de forma passiva, prevenindo infe\u00e7\u00f5es graves ou recorrentes, bem como as suas complica\u00e7\u00f5es a m\u00e9dio e longo prazo. Atualmente, existem diferentes vias de administra\u00e7\u00e3o: endovenosa, subcut\u00e2nea convencional, e subcut\u00e2nea facilitada com hialuronidase recombinante. A escolha da via de administra\u00e7\u00e3o deve ser feita de forma individualizada, com participa\u00e7\u00e3o ativa do doente e orienta\u00e7\u00e3o pelos profissionais de sa\u00fade quanto \u00e0s vantagens e limita\u00e7\u00f5es de cada alternativa. Este protocolo pretende esclarecer sobre as modalidades dispon\u00edveis de tratamento com imunoglobulina, propor orienta\u00e7\u00f5es pr\u00e1ticas para a sua escolha e, com isso, favorecer uma maior ades\u00e3o e efic\u00e1cia terap\u00eautica, promovendo maior estabilidade cl\u00ednica dos doentes.<\/jats:p>","DOI":"10.20344\/amp.24119","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:02:18Z","timestamp":1777914138000},"page":"366-371","source":"Crossref","is-referenced-by-count":1,"title":["Terap\u00eautica Substitutiva com Imunoglobulina nos Defeitos de Produ\u00e7\u00e3o de Anticorpos"],"prefix":"10.20344","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9782-0659","authenticated-orcid":false,"given":"Ana","family":"Bernardino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1033-3178","authenticated-orcid":false,"given":"Nuzhat","family":"Abdurrachid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8785-4097","authenticated-orcid":false,"given":"Cl\u00e1udia","family":"Varandas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5143-7649","authenticated-orcid":false,"given":"Ruben","family":"Duarte Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Em\u00edlia","family":"Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8838-5704","authenticated-orcid":false,"given":"Sara","family":"P. Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3943-1185","authenticated-orcid":false,"given":"Susana","family":"L. Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8464","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"12738","doi-asserted-by":"crossref","unstructured":"Buckley CR. Agammaglobulinemia, by Col. Ogden C. Bruton, MC, USA, Pediatrics, 1952;9:722-728. Pediatrics. 1998;102:213-5.","DOI":"10.1542\/peds.102.S1.213"},{"key":"12739","doi-asserted-by":"crossref","unstructured":"Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125:S182-94.","DOI":"10.1016\/j.jaci.2009.07.053"},{"key":"12740","unstructured":"Garc\u00eda JM, Gamboa P, de la Calle A, Hern\u00e1ndez MD, Caballero MT, Garc\u00eda BE, et al. Diagnosis and management of immunodeficiencies in adults by allergologists. J Investig Allergol Clin Immunol. 2010;20:185-94."},{"key":"12741","doi-asserted-by":"crossref","unstructured":"Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy. J Allergy Clin Immunol. 2006;117:S525-53. Erratum in: J Allergy Clin Immunol. 2006;117:1483.","DOI":"10.1016\/j.jaci.2006.01.015"},{"key":"12742","doi-asserted-by":"crossref","unstructured":"Wasserman RL. Personalized therapy: immunoglobulin replacement for antibody deficiency. Immunol Allergy Clin North Am. 2019;39:95-111.","DOI":"10.1016\/j.iac.2018.08.001"},{"key":"12743","doi-asserted-by":"crossref","unstructured":"Herman KE, Tuttle KL. Overview of secondary immunodeficiency. Allergy Asthma Proc. 2024;45:347-54.","DOI":"10.2500\/aap.2024.45.240063"},{"key":"12744","doi-asserted-by":"crossref","unstructured":"Seidel MG. Rethinking PIDs: why the distinction between primary and secondary immune disorders is more frequently relevant than that between inborn and acquired errors of immunity. J Allergy Clin Immunol. 2024;153:1543-45.","DOI":"10.1016\/j.jaci.2024.01.018"},{"key":"12745","doi-asserted-by":"crossref","unstructured":"Patel SY, Carbone J, Jolles S. The expanding field of secondary antibody deficiency: causes, diagnosis, and management. Front Immunol. 2019;10:33.","DOI":"10.3389\/fimmu.2019.00033"},{"key":"12746","doi-asserted-by":"crossref","unstructured":"Demirdag YY, Gupta S. Update on infections in primary antibody deficiencies. Front Immunol. 2021;12:634181.","DOI":"10.3389\/fimmu.2021.634181"},{"key":"12747","doi-asserted-by":"crossref","unstructured":"Lee JL, Mohamed Shah N, Makmor-Bakry M, Islahudin FH, Alias H, Noh LM et al. A systematic review and meta-regression analysis on the impact of increasing IgG trough level on infection rates in primary immunodeficiency patients on intravenous IgG therapy. J Clin Immunol. 2020;40:682-98.","DOI":"10.1007\/s10875-020-00788-5"},{"key":"12748","doi-asserted-by":"crossref","unstructured":"Ponsford MJ, Price C, Farewell D, Greene G, Moore C, Perry M, et al. Increased respiratory viral detection and symptom burden among patients with primary antibody deficiency: results from the BIPAD study. J Allergy Clin Immunol Pract. 2021;9:735-44.e6.","DOI":"10.1016\/j.jaip.2020.08.016"},{"key":"12749","doi-asserted-by":"crossref","unstructured":"Sriaroon P, Ballow M. Immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am. 2015;35:713-30.","DOI":"10.1016\/j.iac.2015.07.006"},{"key":"12750","doi-asserted-by":"crossref","unstructured":"Steinbuch M, Audran R. The isolation of IgG from mammalian sera with the aid of caprylic acid. Arch Biochem Biophys. 1969;134:279-84.","DOI":"10.1016\/0003-9861(69)90285-9"},{"key":"12751","doi-asserted-by":"crossref","unstructured":"Dhainaut F, Guillaumat PO, Dib H, Perret G, Sauger A, de Coupade C, et al. In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations. Vox Sang. 2013;104:115-26.","DOI":"10.1111\/j.1423-0410.2012.01648.x"},{"key":"12752","doi-asserted-by":"crossref","unstructured":"Sp\u00e4th PJ, Granata G, La Marra F, Kuijpers TW, Quinti I. On the dark side of therapies with immunoglobulin concentrates: the adverse events. Front Immunol. 2015;6:11.","DOI":"10.3389\/fimmu.2015.00011"},{"key":"12753","doi-asserted-by":"crossref","unstructured":"Bonilla FA. Intravenous and subcutaneous immunoglobulin G replacement therapy. Allergy Asthma Proc. 2016;37:426-31.","DOI":"10.2500\/aap.2016.37.3987"},{"key":"12754","doi-asserted-by":"crossref","unstructured":"Borte M, Bernatowska E, Ochs HD, Roifman CM; Vivaglobin Study Group. Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies. Clin Exp Immunol. 2011;164:357-64.","DOI":"10.1111\/j.1365-2249.2011.04376.x"},{"key":"12755","doi-asserted-by":"crossref","unstructured":"Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20:94-100.","DOI":"10.1023\/A:1006678312925"},{"key":"12756","doi-asserted-by":"crossref","unstructured":"Shapiro RS. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Ann Allergy Asthma Immunol. 2013;111:51-5.","DOI":"10.1016\/j.anai.2013.04.015"},{"key":"12757","unstructured":"Krivan G, Jolles S, Granados EL, Paolantonacci P, Ouaja R, Ciss\u00e9 AO, et al. New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients. Am J Clin Exp Immunol. 2017;6:76-83."},{"key":"12758","doi-asserted-by":"crossref","unstructured":"Sil A, Basu S, Joshi V, Pilania RK, Siniah S, Suri D, et al. Immunoglobulin replacement therapies in inborn errors of immunity: a review. Front Pediatr. 2024;12:1368755.","DOI":"10.3389\/fped.2024.1368755"},{"key":"12759","doi-asserted-by":"crossref","unstructured":"Shapiro RS, Wasserman RL, Bonagura V, Gupta S. Emerging paradigm of primary immunodeficiency disease: individualizing immunoglobulin dose and delivery to enhance outcomes. J Clin Immunol. 2017;37:190-6.","DOI":"10.1007\/s10875-014-9990-x"},{"key":"12760","doi-asserted-by":"crossref","unstructured":"Jolles S, Orange JS, Gardulf A, Stein MR, Shapiro R, Borte M, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol. 2015;179:146-60.","DOI":"10.1111\/cei.12485"},{"key":"12761","doi-asserted-by":"crossref","unstructured":"Yalcin Gungoren E, Yorgun Altunbas M, Dikici U, Meric Z, Eser Simsek I, Kiykim A, et al. Insights into patient experiences with facilitated subcutaneous immunoglobulin therapy in primary immune deficiency: a prospective observational cohort. J Clin Immunol. 2024;44:169.","DOI":"10.1007\/s10875-024-01771-0"},{"key":"12762","doi-asserted-by":"crossref","unstructured":"Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139:S1-S46.","DOI":"10.1016\/j.jaci.2016.09.023"},{"key":"12763","doi-asserted-by":"crossref","unstructured":"Perez E. Future of therapy for inborn errors of immunity. Clin Rev Allergy Immunol. 2022;63:75-89.","DOI":"10.1007\/s12016-021-08916-8"},{"key":"12764","doi-asserted-by":"crossref","unstructured":"Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27:171-8.","DOI":"10.1016\/j.tmrv.2013.05.004"}],"container-title":["Acta M\u00e9dica Portuguesa"],"original-title":[],"link":[{"URL":"https:\/\/www.actamedicaportuguesa.com\/revista\/index.php\/amp\/article\/download\/24119\/15947","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.actamedicaportuguesa.com\/revista\/index.php\/amp\/article\/download\/24119\/15947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:02:30Z","timestamp":1777914150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.actamedicaportuguesa.com\/revista\/index.php\/amp\/article\/view\/24119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,4]]}},"URL":"https:\/\/doi.org\/10.20344\/amp.24119","relation":{},"ISSN":["1646-0758","0870-399X"],"issn-type":[{"value":"1646-0758","type":"electronic"},{"value":"0870-399X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,4]]}}}